HER2 mutant non-small cell lung cancer

4 trials 3 recruiting MedDRA PT
4 Registered trials
3 Recruiting
4 Unique sponsors
4 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 4
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Antibody-drug conjugate (ADC) 1 substance
Monoclonal antibody 1 substance
Phase III: 1 Phase II: 1 Phase I/II: 1 Phase I (Other): 1

Filter these 4 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 4 trials

Phase III

1 trial
  • AstraZeneca AB Commercial
    TRASTUZUMAB DERUXTECAN
    2023-503674-20-00 9 countries 2021 n=160
    Ended

Phase II

1 trial

Phase I/II

1 trial
  • BioNTech SE Commercial
    BNT326; BNT327
    2024-519344-32-00 4 countries 2026 n=88
    Recruiting

Phase I (Other)

1 trial
  • Arrivent Biopharma Inc. Commercial
    IMP not specified
    2023-508349-42-00 4 countries 2022 n=32
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Arrivent Biopharma Inc. Commercial 1 Phase I (Other) 1
AstraZeneca AB Commercial 1 Phase III 0
BioNTech SE Commercial 1 Phase I/II 1
Unicancer Academic 1 Phase II 1
New trials by year
2021
1
2022
1
2025
1
2026
1
← All indication landscapes